Soluble complement receptor type 1 prevents human complement-mediated damage of the rabbit isolated heart

Area of Science:

• Cardiovascular Research
• Immunology
• Biochemistry

Background:

• Complement system activation can lead to significant tissue damage, particularly in cardiovascular tissues.
• Understanding the mechanisms of complement-mediated myocardial injury is crucial for developing therapeutic interventions.

Purpose of the Study:

• To evaluate the protective effect of recombinant human soluble complement receptor 1 (sCR1) against complement-induced myocardial injury.
• To investigate the role of sCR1 in preventing tissue damage and functional impairment caused by complement activation.

Main Methods:

• An isolated rabbit heart model was perfused with Krebs-Henseleit buffer containing human plasma.
• Complement activation was induced using normal human plasma (NHP), with or without sCR1 (20 nM).
• Functional parameters (pressures, dP/dt, lymphatic flow) and ultrastructural changes were assessed.

Main Results:

• Perfusion with NHP caused significant myocardial injury, including increased diastolic and coronary perfusion pressures, decreased developed pressure, and reduced dP/dt.
• Complement activation also increased cardiac lymphatic fluid flow and led to ultrastructural tissue damage.
• sCR1 administration prevented all observed complement-mediated functional and structural alterations.

Conclusions:

• Recombinant human soluble CR1 (sCR1) effectively protects against complement-mediated myocardial injury.
• sCR1 inhibits the formation of the terminal C5b-9 complex, thereby preventing tissue damage.
• sCR1 demonstrates significant therapeutic potential in conditions involving complement system activation.